HRP20100681T1 - Derivati hinaholina korisni za tretman periferne arterijske bolesti i kao inhibitori fosfodiesteraze - Google Patents

Derivati hinaholina korisni za tretman periferne arterijske bolesti i kao inhibitori fosfodiesteraze Download PDF

Info

Publication number
HRP20100681T1
HRP20100681T1 HR20100681T HRP20100681T HRP20100681T1 HR P20100681 T1 HRP20100681 T1 HR P20100681T1 HR 20100681 T HR20100681 T HR 20100681T HR P20100681 T HRP20100681 T HR P20100681T HR P20100681 T1 HRP20100681 T1 HR P20100681T1
Authority
HR
Croatia
Prior art keywords
compound
treatment
peripheral arterial
image
use according
Prior art date
Application number
HR20100681T
Other languages
English (en)
Inventor
Franklin Richard
Original Assignee
Shire Biopharmaceuticals Holdings Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biopharmaceuticals Holdings Ireland Limited filed Critical Shire Biopharmaceuticals Holdings Ireland Limited
Publication of HRP20100681T1 publication Critical patent/HRP20100681T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Spoj formulenjegov uravnotezeni oblik, neka farmaceutski prihvatljiva sol ovog spoja ili njegovog uravnotezenog oblika, gdje, R1 predstavlja H, C1-6 alkil, C2-6 alkenil, C2-8 alkinil, C1-6 alkoksi, ili C6-10 aril; R2 predstavlja R3 predstavlja OH, halogen, SH, O-C1-6 alkil ili NH2; iX i Y svaki neovisno, predstavlja H ili halogen, za uporabu kod povisenih sadrzaja lipoproteina visoke gustoce i apolipoproteina u plazmi, ili za upotrebu u tretmanu periferne arterijske bolesti, ateroskleroze, povremenog sepanja, kongestivne srcane smetnje, neke bolesti povezane s povisenom agregacijom plocica, tromboze, mozdanog udara ili seksualne disfunkcije. Patent sadrzi jos 15 patentnih zahtjeva.

Claims (16)

1. Spoj formule [image] njegov uravnoteženi oblik, neka farmaceutski prihvatljiva sol ovog spoja ili njegovog uravnoteženog oblika, gdje, R1 predstavlja H, C1-6 alkil, C2-6 alkenil, C2-8 alkinil, C1-6 alkoksi, ili C6-10 aril; R2 predstavlja [image] R3 predstavlja OH, halogen, SH, O-C1-6 alkil ili NH2; i X i Y svaki neovisno, predstavlja H ili halogen, za uporebu kod povišenih sadržaja lipoproteina visoke gustoće i apolipoproteina u plazmi, ili za upotrebu u tretmanu periferne arterijske bolesti, ateroskleroze, povremenog šepanja, kongestivne srčane smetnje, neke bolesti povezane s povišenom agregacijom pločica, tromboze, moždanog udara ili seksualne disfunkcije.
2. Spoj za upotrebu prema Zahtjevu 1, pri čemu taj spoj ima formulu [image]
3. Spoj za upotrebu prema Zahtjevu 1, pri čemu R2 predstavlja [image]
4. Spoj za upotrebu prema Zahtjevu 1, pri čemu R1 predstavlja H ili C1-6 alkil.
5. Spoj za upotrebu prema Zahtjevu 1, pri čemu R1 predstavlja H.
6. Spoj za upotrebu prema Zahtjevu 1, pri čemu X predstavlja H ili halogen.
7. Spoj za upotrebu prema Zahtjevu 1, pri čemu Y predstavlja H ili Cl.
8. Spoj za upotrebu prema Zahtjevu 1, pri čemu X predstavlja Cl.
9. Spoj za upotrebu prema Zahtjevu 1, pri čemu Y predstavlja Cl.
10. Spoj za upotrebu prema Zahtjevu 1, pri čemu taj spoj predstavlja [image]
11. Spoj prema Zahtjevu 1, za upotrebu u tretmanu periferne arterijske bolesti.
12. Spoj prema Zahtjevu 1, za upotrebu u tretmanu ateroskleroze.
13. Spoj prema Zahtjevu 1, za upotrebu u tretmanu povremenog šepanja.
14. Spoj prema Zahtjevu 1, za upotrebu u tretmanu kongestivne srčane smetnje.
15. Spoj prema Zahtjevu 1, za upotrebu u tretmanu moždanog udara.
16. Spoj prema Zahtjevu 1, za upotrebu u tretmanu seksualne disfunkcije.
HR20100681T 2004-08-04 2010-12-08 Derivati hinaholina korisni za tretman periferne arterijske bolesti i kao inhibitori fosfodiesteraze HRP20100681T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59843204P 2004-08-04 2004-08-04

Publications (1)

Publication Number Publication Date
HRP20100681T1 true HRP20100681T1 (hr) 2011-01-31

Family

ID=35839972

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100681T HRP20100681T1 (hr) 2004-08-04 2010-12-08 Derivati hinaholina korisni za tretman periferne arterijske bolesti i kao inhibitori fosfodiesteraze

Country Status (22)

Country Link
US (1) US20060030574A1 (hr)
EP (2) EP1949893B1 (hr)
JP (1) JP4758993B2 (hr)
CN (1) CN101014344A (hr)
AT (1) ATE484278T1 (hr)
AU (1) AU2005271275A1 (hr)
BR (1) BRPI0513943A (hr)
CA (1) CA2575512C (hr)
CY (1) CY1110881T1 (hr)
DE (1) DE602005024192D1 (hr)
DK (1) DK1949893T3 (hr)
EA (1) EA200700406A1 (hr)
ES (1) ES2353848T3 (hr)
HR (1) HRP20100681T1 (hr)
MX (1) MX2007001513A (hr)
NO (1) NO20071098L (hr)
PL (1) PL1949893T3 (hr)
PT (1) PT1949893E (hr)
RS (1) RS51519B (hr)
SI (1) SI1949893T1 (hr)
WO (1) WO2006017823A2 (hr)
ZA (1) ZA200701850B (hr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2382547A1 (en) * 1999-09-21 2001-03-29 Stephen R. Hanson Methods and compositions for treating platelet-related disosders
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
GB0623750D0 (en) * 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
US8304420B2 (en) * 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808952D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808967D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2862966A (en) * 1958-12-02 archo
US1947926A (en) * 1934-02-20 Seed grain dressings and process of
US2732403A (en) * 1956-01-24 Chclj
US2256999A (en) * 1939-03-08 1941-09-23 Du Pont Nitration of organic compounds
US2469695A (en) * 1946-02-02 1949-05-10 Eastman Kodak Co Nitroaminobenzene ester compounds
US2608584A (en) * 1947-03-19 1952-08-26 Nopco Chem Co Preparation of n-alkyl arylamines
US2883435A (en) * 1956-10-10 1959-04-21 Gen Aniline & Film Corp Purification of 1,2-dichloro-4-nitrobenzene
US3313854A (en) * 1961-11-20 1967-04-11 Universal Oil Prod Co Preparation of para-nitrodiphenylamines utilizing a copper oxide catalyst
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
USRE31617E (en) * 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
JPS49132019A (hr) * 1973-02-26 1974-12-18
DE2400887A1 (de) * 1974-01-09 1975-08-28 Bayer Ag Verfahren zur herstellung von nitroderivaten aromatischer verbindungen
JPS5752352B2 (hr) * 1974-02-28 1982-11-06
US3983119A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3983120A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3988340A (en) * 1975-01-23 1976-10-26 Bristol-Myers Company 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones
JPS5251379A (en) * 1975-10-24 1977-04-25 Sumitomo Chem Co Ltd Preparation 3,4-dihydro-2(1h)-quinazoline derivates
JPS5291885A (en) * 1976-01-23 1977-08-02 Sumitomo Chem Co Ltd 3,4-dihydro-2(1h)-quinazolinone derivatives
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
US4146718A (en) * 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US4208521A (en) * 1978-07-31 1980-06-17 Bristol-Myers Company Process for the preparation of imidazo[2,1-b]quinazolinones
EP0028489B1 (en) * 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
ZW16481A1 (en) * 1980-08-15 1982-03-10 Hoffmann La Roche Novel imidazoquinazoline derivatives
US4357330A (en) * 1981-07-30 1982-11-02 Bristol-Myers Company Pharmaceutical compositions
US4444777A (en) * 1981-07-30 1984-04-24 Bristol-Myers Company Pharmaceutical compositions of anagrelide and sulfinpyrazone
US4455311A (en) * 1981-08-28 1984-06-19 Hoffmann-La Roche Inc. Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4847276A (en) * 1988-09-06 1989-07-11 Merrell Dow Pharmaceuticals Inc. Treatment of thromobocytosis with 5-(4-chlorophenyl)-2,4-diemthyl-3H-1,2,4-triazole-3-thione
GB8824496D0 (en) * 1988-10-19 1988-11-23 Beecham Group Plc Process
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
US5043327A (en) * 1989-07-18 1991-08-27 Janssen Pharmaceutica N.V. Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives, compositions and use
US5391737A (en) * 1991-05-22 1995-02-21 Egis Gyogyszergyar Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one
US5306709A (en) * 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
US6024975A (en) * 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
CA2171073A1 (en) * 1995-12-04 1997-06-05 Philip C. Lang Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6110471A (en) * 1996-09-13 2000-08-29 The Board Of Trustees Of The Leland Stanford Junior University Non-hormonal method of contraception
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
AU9621598A (en) * 1997-10-20 1999-05-10 Novo Nordisk A/S Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6156753A (en) * 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
CA2382547A1 (en) * 1999-09-21 2001-03-29 Stephen R. Hanson Methods and compositions for treating platelet-related disosders
US6194420B1 (en) * 1999-11-30 2001-02-27 Roberts Laboratories Inc. 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
US6388073B1 (en) * 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
US20030235609A1 (en) * 2002-01-25 2003-12-25 Lautt Wilfred Wayne Use of cholinesterase antagonists to treat insulin resistance
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US20030114673A1 (en) * 2002-05-29 2003-06-19 Lang Philip C. 2-amino-5,6-dihalo-3,4-dihydroquinazolines with blood platelet reducing properties
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20040209907A1 (en) * 2003-01-23 2004-10-21 Richard Franklin Formulation and methods for the treatment of thrombocythemia
EP1776108A1 (en) * 2004-06-23 2007-04-25 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases

Also Published As

Publication number Publication date
DK1949893T3 (da) 2011-01-31
ZA200701850B (en) 2008-08-27
SI1949893T1 (sl) 2011-02-28
ES2353848T3 (es) 2011-03-07
CA2575512C (en) 2010-12-14
CY1110881T1 (el) 2015-06-10
CA2575512A1 (en) 2006-02-16
CN101014344A (zh) 2007-08-08
BRPI0513943A (pt) 2008-05-20
JP2008509163A (ja) 2008-03-27
PT1949893E (pt) 2011-01-04
EP1949893A2 (en) 2008-07-30
US20060030574A1 (en) 2006-02-09
EA200700406A1 (ru) 2007-08-31
WO2006017823A3 (en) 2006-05-04
AU2005271275A1 (en) 2006-02-16
RS51519B (en) 2011-06-30
EP1949893A3 (en) 2008-08-20
MX2007001513A (es) 2007-03-27
WO2006017823A2 (en) 2006-02-16
DE602005024192D1 (de) 2010-11-25
ATE484278T1 (de) 2010-10-15
EP1778235A2 (en) 2007-05-02
PL1949893T3 (pl) 2011-04-29
EP1949893B1 (en) 2010-10-13
EP1778235A4 (en) 2008-08-20
NO20071098L (no) 2007-05-03
JP4758993B2 (ja) 2011-08-31

Similar Documents

Publication Publication Date Title
HRP20100681T1 (hr) Derivati hinaholina korisni za tretman periferne arterijske bolesti i kao inhibitori fosfodiesteraze
RS51376B (en) HINAZOLINE DERIVATIVES AND THEIR USE IN THROMBOCYTEMIA TREATMENT
RS51471B (en) BIPHYNYLOXYXIC ACID DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES
RU2006134003A (ru) Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
ATE463483T1 (de) 6-substituierte isochinolinderivate als rock-1- inhibitoren
SI3106463T1 (en) Compounds of substituted pyrazolo (1,5-) pyrimidine as inhibitors of TRK kinase
WO2004050022B1 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
RU2006146632A (ru) Производные хиназолинона, полезные в качестве ванилоидных антагонистов
WO2004052893A3 (en) Substituted dihydropyrano indole-3,4-dione derivatives and 3-oxoacetic acid substituted 2-hydroxymethylindole derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
RU2008145971A (ru) Производные 2-тиоксантина, действующие в качестве ингибиторов мро
RS54260B1 (en) AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT
EA200900358A1 (ru) Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
PE20050480A1 (es) Acido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0] non-1(7)-en-2-il)alquil]fosfonico y derivados
HRP20070430T3 (hr) (3-okso-3,4-dihidro-kiinoksalin-2-il-amino)-benzamidni derivati i srodni spojevi kao inhibitori glikogen-fosforilaze za liječenje dijabetesa i pretilosti
NO20034595D0 (no) Kinolin- og kinazolinderivater med azolylgruppe
EA200300424A1 (ru) Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов
MA30694B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
NO20051011L (no) Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister
DE602005017162D1 (de) 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i
RU2005121908A (ru) Производные зн-хиназолин-4-она
ATE276257T1 (de) Pyrazinonderivate
EA200400219A1 (ru) Производные хинолина и их использование в качестве противоопухолевых средств
EA200700322A1 (ru) Оксазолидиноны, содержащие оксиндолы, в качестве антибактериальных агентов
JP2007507467A5 (hr)
ATE149494T1 (de) Benzopyranderivate und verfahren zu deren herstellung